<DOC>
	<DOCNO>NCT02620878</DOCNO>
	<brief_summary>The purpose study determine safety , feasibility efficacy ( respect sensor- augment pump therapy ) Artificial Pancreas ( AP ) prototype day night closed-loop control child adolescent type 1 diabetes .</brief_summary>
	<brief_title>Artificial Pancreas Pediatric Patients ( PEDarPAN )</brief_title>
	<detailed_description>The AP prototype base Modular Model Predictive Control algorithm ( MMPC ) implement Diabetes Assistant ( DiAs ) wearable platform . The study divide two part : first part serve 3 day pilot study conduct hotel/residence near hospital . The investigator recruit 6/8 child ( 5-12 year ) and/or 6/8 adolescent ( 12-18 year ) , type 1 diabetes experience insulin pump . DiAs use 72 continuous hour day night . If part 1 successfully , 2-3 month , study move second part ( main part ) , consist cross-over randomize study conduct camp setting . The participant randomly assign treatment arm ( Artificial Pancreas ) control arm ( sensor-augmented insulin pump ) . Then patient assign arm . Each treatment apply 3 consecutive day . During first period ( day 1-3 ) patient activites diet second period ( day 5-7 ) . The investigator recruit 30/40 child ( 5-12 year ) and/or 30/40 adolescent ( 12-18 year ) , affect type 1 diabetes experience insulin pump therapy . The study permission Ethics Committee reference permission `` clinical investigation device CE mark '' Health Ministry .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>1 . Clinical diagnosis type 1 diabetes · The diagnosis type 1 diabetes base investigator 's judgment · C peptide level antibody determination require 2 . Daily insulin therapy ≥ 12 month 3 . Insulin pump therapy ≥ 3 month 4 . Age 618 year 5 . A1C &lt; 10 6 . Avoidance acetaminophencontaining medication ( i.e . Tachipirina , tachidol , tachiflu ) wear continuous glucose monitor . 7 . Willingness wear continuous glucose sensor 8 . Female subject sexually active must acceptable method contraception ( e.g . oral contraceptive pill , diaphragm , IUD ) . 1 . Diabetic ketoacidosis past month 2 . Hypoglycemic seizure loss consciousness past 3 month 3 . History seizure disorder ( except hypoglycemic seizure ) 4 . A1C &gt; 10 5 . History heart disease include coronary artery disease , heart failure , arrhythmias 6 . Cystic fibrosis 7 . Current use oral glucocorticoid , betablockers medication , judgment investigator would contraindication participation study . 8 . History ongoing renal disease ( microalbuminuria ) . 9 . Subjects require intermediate longacting insulin ( NPH , Detemir , Glargine Degludec ) . 10 . Subjects require antidiabetic medication insulin ( oral injectable ) . 11 . Pregnancy verbal denial pregnancy obtain telephone informed consent , pregnancy test perform camp study device assign . 12 . Sexually active female practice acceptable contraceptive method prevent pregnancy . 13 . Presence febrile illness within 24 hour admission acetaminophen use wear CGM . The subject may reschedule Research House/hotel admission criterion meet . The camp study subject participate trial condition meet . 14 . Medical psychiatric condition judgment investigator might interfere completion protocol : Inpatient psychiatric treatment past 6 month Uncontrolled adrenal insufficiency Alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Artificial pancreas</keyword>
	<keyword>SAP therapy</keyword>
	<keyword>child</keyword>
	<keyword>adolescent</keyword>
	<keyword>type 1 diabetes</keyword>
</DOC>